Table 3 Q-genie scores
First Author Last Name, Year | Reported conflicts of interest | Reported study limitations | Q-Genie Score | Quality Assessment |
|---|---|---|---|---|
Agrawal, 2011 | Drs. LJ Bierut, J. Rice, A. Goate and S Saccone are listed as inventors on the patent "Markers for Addiction" (US 20,070,258,898): covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Dr. Bierut has acted as a consultant for Pfizer, Inc. in 2008. All other authors report no competing interests | SAGE study was ascertained for alcohol dependence led to a high level of comorbidity in the cannabis dependent cases and exposed controls Use of controls with other forms of substance dependence but not cannabis dependence protected against signals that may have been less specific Power computations revealed that minor allele frequencies ranging from 15–40% association signals with odds ration exceeding 1.45 were able to be detected | 53 | Good Quality |
Agrawal, 2014 | Laura J. Bierut is listed as an inventor on Issued U.S. Patent 8,080,371,“Markers for Addiction” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction | The sample was ascertained from three family studies of substance use disorders for the express purpose of identifying genetic variants for alcoholism, nicotine and cocaine dependence and related pathology Differences in DSM-IV and DSM-5 criteria leading to different assessments of withdrawal and diagnosis of CUD across study populations | 55 | Good quality |
Demontis, 2019 | T. Werge has been a lecturer and advisor to H. Lundbeck A/S. T.E. Thorgeirsson, D.F. Gudbjartsson, G.W. Reginsson, H. Stefansson and K. Stefansson are employees of deCODE genetics/Amgen | None reported | 57 | Good quality |
Minica, 2015 | None | No statistically significant GWAS findings that pass the threshold p < 1.0 × 10–8 | 49 | Moderate quality |
Pasman, 2018 | P.F., S.L.E. and members of the 23andMe Research Team are employees of 23andMe Inc. J.A.R.-Q. was on the speakers’ bureau and/or acted as consultant for Eli Lilly, Janssen- Cilag, Novartis, Shire, Lundbeck, Almirall, BRAINGAZE, Sincrolab and Rubió in the last 5 years. He also received travel awards (air tickets and hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire and Eli Lilly. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the last 5 years: Eli Lilly, Lundbeck, Janssen- Cilag, Actelion, Shire, Ferrer and Rubió | Lifetime cannabis was analyzed as a single dichotomous measure combining experimental and regular users in a single group The power of some analyses may have been limited | 52 | Good quality |
Sherva, 2016 | Dr Kranzler reports being a consultant or an advisory board member for Alkermes, Indivior, Lundbeck, and Otsuka (unrelated to the present study) and being a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which is supported by AbbVie, Ethypharm, Lilly, Lundbeck, and Pfizer. No other disclosures were reported | One of the significant SNPs identified (rs143244591 on chromosome 3) has little supportive evidence for association from other SNPs in the region None of the GWAS SNPs identified in the full GWAS analysis are rare Lack of evidence of associations in both the European American and African American participants The Yale-Penn samples who underwent genotyping on the HumanOmni1-Quad and Human Core Exome chips showed more consistent results than the corresponding SAGE population The cohorts used have higher rates of polysubstance dependence than the general population and may not be generalizable to individuals who only use cannabis | 52 | Good quality |